phosphorylated p akt Search Results


antibodies against phosphorylated (p-)akt  (Abmart Inc)
90
Abmart Inc antibodies against phosphorylated (p-)akt
Effects of quercetin on the <t>phosphorylation</t> <t>of</t> <t>Akt</t> in LPS-stimulated RAW264.7 cells. (A and B) The cells were pretreated with different concentrations of quercetin (5,10 and 20 µM) for 1 h and then stimulated with LPS (1 µg/ml) for another 6 h. (A) After different treatments, the protein levels of <t>p-Akt,</t> Akt and GAPDH were determined using western blot analysis and (B) the results were statistically analyzed. (C-G) RAW264.7 cells were pretreated with quercetin (20 µM) and AKT inhibitor (MK-2206; 5 µM) for 1 h in 6-well microplates and stimulated with LPS (1 µg/ml) for 6 or 24 h. The (C) mRNA and (D and E) protein expression levels of TNF-α, IL-6 and IL-1β were analyzed using reverse transcription-quantitative PCR and western blot analysis, respectively. (D) Representative western blots and (E) quantified results. (F and G) The protein levels of p-Akt, Akt were analyzed using western blot analysis. (F) Representative western blots and (G) quantified results. ## P<0.01 vs. non-intervention group; ** P<0.01 vs. LPS alone group; & P<0.05, && P<0.01 vs. quercetin treatment group. LPS, lipopolysaccharide; p, <t>phosphorylated.</t>
Antibodies Against Phosphorylated (P )Akt, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against phosphorylated (p-)akt/product/Abmart Inc
Average 90 stars, based on 1 article reviews
antibodies against phosphorylated (p-)akt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
phosphorylated (p-) akt  (Affinity Biosciences)
90
Affinity Biosciences phosphorylated (p-) akt
MiR-107 overexpression suppressed the <t>PI3K/Akt</t> signaling pathway in FaDu cells. (a) After transfection for 48 h, the protein levels of <t>p-PI3K,</t> PI3K, p-Akt, and Akt were evaluated.
Phosphorylated (P ) Akt, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated (p-) akt/product/Affinity Biosciences
Average 90 stars, based on 1 article reviews
phosphorylated (p-) akt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
phosphorylated (p-)akt 310021 antibody  (Chengdu Zen Bioscience)
90
Chengdu Zen Bioscience phosphorylated (p-)akt 310021 antibody
Results of western blot analysis. (A) Representative western blots of rat chondrocytes. The average relative expression of (B) LC3II/I, (C) <t>p-AKT/AKT</t> and (D) p-mTOR/mTOR from rat chondrocytes. (E) Representative western blots of human chondrocytes. The average relative expression of (F) LC3II/I, (G) p-AKT/AKT, and (H) p-mTOR/mTOR from human chondrocytes. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Con, control group; DEX, dexamethasone group (200 µM); DEX + Li, dexamethasone (200 µM) combined with lithium chloride (10 mM) group; p-AKT, <t>phosphorylated</t> AKT; p-mTOR, phosphorylated mTOR; p-, phosphorylated.
Phosphorylated (P )Akt 310021 Antibody, supplied by Chengdu Zen Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated (p-)akt 310021 antibody/product/Chengdu Zen Bioscience
Average 90 stars, based on 1 article reviews
phosphorylated (p-)akt 310021 antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
phosphorylated akt (p-akt  (Abmart Inc)
90
Abmart Inc phosphorylated akt (p-akt
Results of western blot analysis. (A) Representative western blots of rat chondrocytes. The average relative expression of (B) LC3II/I, (C) <t>p-AKT/AKT</t> and (D) p-mTOR/mTOR from rat chondrocytes. (E) Representative western blots of human chondrocytes. The average relative expression of (F) LC3II/I, (G) p-AKT/AKT, and (H) p-mTOR/mTOR from human chondrocytes. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Con, control group; DEX, dexamethasone group (200 µM); DEX + Li, dexamethasone (200 µM) combined with lithium chloride (10 mM) group; p-AKT, <t>phosphorylated</t> AKT; p-mTOR, phosphorylated mTOR; p-, phosphorylated.
Phosphorylated Akt (P Akt, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated akt (p-akt/product/Abmart Inc
Average 90 stars, based on 1 article reviews
phosphorylated akt (p-akt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
phosphorylated (p‑)akt  (Chengdu Zen Bioscience)
90
Chengdu Zen Bioscience phosphorylated (p‑)akt
Results of western blot analysis. (A) Representative western blots of rat chondrocytes. The average relative expression of (B) LC3II/I, (C) <t>p-AKT/AKT</t> and (D) p-mTOR/mTOR from rat chondrocytes. (E) Representative western blots of human chondrocytes. The average relative expression of (F) LC3II/I, (G) p-AKT/AKT, and (H) p-mTOR/mTOR from human chondrocytes. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Con, control group; DEX, dexamethasone group (200 µM); DEX + Li, dexamethasone (200 µM) combined with lithium chloride (10 mM) group; p-AKT, <t>phosphorylated</t> AKT; p-mTOR, phosphorylated mTOR; p-, phosphorylated.
Phosphorylated (P‑)Akt, supplied by Chengdu Zen Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated (p‑)akt/product/Chengdu Zen Bioscience
Average 90 stars, based on 1 article reviews
phosphorylated (p‑)akt - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
rabbit anti-rat phosphorylated (p)-akt pab  (Wanleibio)
90
Wanleibio rabbit anti-rat phosphorylated (p)-akt pab
Results of western blot analysis. (A) Representative western blots of rat chondrocytes. The average relative expression of (B) LC3II/I, (C) <t>p-AKT/AKT</t> and (D) p-mTOR/mTOR from rat chondrocytes. (E) Representative western blots of human chondrocytes. The average relative expression of (F) LC3II/I, (G) p-AKT/AKT, and (H) p-mTOR/mTOR from human chondrocytes. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Con, control group; DEX, dexamethasone group (200 µM); DEX + Li, dexamethasone (200 µM) combined with lithium chloride (10 mM) group; p-AKT, <t>phosphorylated</t> AKT; p-mTOR, phosphorylated mTOR; p-, phosphorylated.
Rabbit Anti Rat Phosphorylated (P) Akt Pab, supplied by Wanleibio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti-rat phosphorylated (p)-akt pab/product/Wanleibio
Average 90 stars, based on 1 article reviews
rabbit anti-rat phosphorylated (p)-akt pab - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
phosphorylated p‑akt (ser473) (cat. no. e1a0016)  (EnoGene Inc)
90
EnoGene Inc phosphorylated p‑akt (ser473) (cat. no. e1a0016)
Results of western blot analysis. (A) Representative western blots of rat chondrocytes. The average relative expression of (B) LC3II/I, (C) <t>p-AKT/AKT</t> and (D) p-mTOR/mTOR from rat chondrocytes. (E) Representative western blots of human chondrocytes. The average relative expression of (F) LC3II/I, (G) p-AKT/AKT, and (H) p-mTOR/mTOR from human chondrocytes. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Con, control group; DEX, dexamethasone group (200 µM); DEX + Li, dexamethasone (200 µM) combined with lithium chloride (10 mM) group; p-AKT, <t>phosphorylated</t> AKT; p-mTOR, phosphorylated mTOR; p-, phosphorylated.
Phosphorylated P‑Akt (Ser473) (Cat. No. E1a0016), supplied by EnoGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated p‑akt (ser473) (cat. no. e1a0016)/product/EnoGene Inc
Average 90 stars, based on 1 article reviews
phosphorylated p‑akt (ser473) (cat. no. e1a0016) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
polyclonal antibodies against phosphorylated (p)-akt (af0016)  (Affinity Biologicals)
90
Affinity Biologicals polyclonal antibodies against phosphorylated (p)-akt (af0016)
Treatment with angelicin alters the protein expression levels of PI3K, <t>p-Akt</t> and total Akt in HepG2 and Huh-7 cells in vitro . (A) Representative blots demonstrating PI3K, p-Akt and total Akt protein expression levels in HepG2 and Huh-7 cells, following treatment with various concentrations of angelicin. (B) PI3K blots were semi-quantified using densitometry analysis of the protein bands and normalized to GAPDH. (C) p-Akt/Akt blots were semi-quantified using densitometry analysis of the protein bands. (D) Effects of LY294002 on angelicin-induced apoptosis. Cells were treated with the PI3K inhibitor LY294002 (3 mM) for 1 h prior to treatment with angelicin. The percentage of apoptotic cells following treatment with angelicin in the presence or absence of LY294002 was assessed using Annexin V-fluorescein isothiocyanate/propidium iodide staining and flow cytometry. Data are expressed as the mean ± standard deviation of 3 independent experiments. *P<0.05, **P<0.01 vs. the control group (0 µM angelicin); # P<0.05 vs. the DMSO group. PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; p-, phosphorylated; DMSO, dimethyl sulfoxide; Akt, RAC-α serine/threonine-protein kinase.
Polyclonal Antibodies Against Phosphorylated (P) Akt (Af0016), supplied by Affinity Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal antibodies against phosphorylated (p)-akt (af0016)/product/Affinity Biologicals
Average 90 stars, based on 1 article reviews
polyclonal antibodies against phosphorylated (p)-akt (af0016) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Effects of quercetin on the phosphorylation of Akt in LPS-stimulated RAW264.7 cells. (A and B) The cells were pretreated with different concentrations of quercetin (5,10 and 20 µM) for 1 h and then stimulated with LPS (1 µg/ml) for another 6 h. (A) After different treatments, the protein levels of p-Akt, Akt and GAPDH were determined using western blot analysis and (B) the results were statistically analyzed. (C-G) RAW264.7 cells were pretreated with quercetin (20 µM) and AKT inhibitor (MK-2206; 5 µM) for 1 h in 6-well microplates and stimulated with LPS (1 µg/ml) for 6 or 24 h. The (C) mRNA and (D and E) protein expression levels of TNF-α, IL-6 and IL-1β were analyzed using reverse transcription-quantitative PCR and western blot analysis, respectively. (D) Representative western blots and (E) quantified results. (F and G) The protein levels of p-Akt, Akt were analyzed using western blot analysis. (F) Representative western blots and (G) quantified results. ## P<0.01 vs. non-intervention group; ** P<0.01 vs. LPS alone group; & P<0.05, && P<0.01 vs. quercetin treatment group. LPS, lipopolysaccharide; p, phosphorylated.

Journal: Experimental and Therapeutic Medicine

Article Title: Assessing the anti-inflammatory effects of quercetin using network pharmacology and in vitro experiments

doi: 10.3892/etm.2022.11230

Figure Lengend Snippet: Effects of quercetin on the phosphorylation of Akt in LPS-stimulated RAW264.7 cells. (A and B) The cells were pretreated with different concentrations of quercetin (5,10 and 20 µM) for 1 h and then stimulated with LPS (1 µg/ml) for another 6 h. (A) After different treatments, the protein levels of p-Akt, Akt and GAPDH were determined using western blot analysis and (B) the results were statistically analyzed. (C-G) RAW264.7 cells were pretreated with quercetin (20 µM) and AKT inhibitor (MK-2206; 5 µM) for 1 h in 6-well microplates and stimulated with LPS (1 µg/ml) for 6 or 24 h. The (C) mRNA and (D and E) protein expression levels of TNF-α, IL-6 and IL-1β were analyzed using reverse transcription-quantitative PCR and western blot analysis, respectively. (D) Representative western blots and (E) quantified results. (F and G) The protein levels of p-Akt, Akt were analyzed using western blot analysis. (F) Representative western blots and (G) quantified results. ## P<0.01 vs. non-intervention group; ** P<0.01 vs. LPS alone group; & P<0.05, && P<0.01 vs. quercetin treatment group. LPS, lipopolysaccharide; p, phosphorylated.

Article Snippet: Antibodies against phosphorylated (p-)Akt (cat. no. T55561) and Akt (cat. no. T40067) were obtained from Abmart.

Techniques: Phospho-proteomics, Western Blot, Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction

MiR-107 overexpression suppressed the PI3K/Akt signaling pathway in FaDu cells. (a) After transfection for 48 h, the protein levels of p-PI3K, PI3K, p-Akt, and Akt were evaluated.

Journal: Bioengineered

Article Title: Overexpression of microRNA-107 suppressed proliferation, migration, invasion, and the PI3K/Akt signaling pathway and induced apoptosis by targeting Nin one binding (NOB1) protein in a hypopharyngeal squamous cell carcinoma cell line (FaDu)

doi: 10.1080/21655979.2022.2051266

Figure Lengend Snippet: MiR-107 overexpression suppressed the PI3K/Akt signaling pathway in FaDu cells. (a) After transfection for 48 h, the protein levels of p-PI3K, PI3K, p-Akt, and Akt were evaluated.

Article Snippet: The information of antibodies used in immunoblotting was as below: cyclin D1 (A19038), cyclin-dependent kinase 4 (CDK4, A0366), caspase-3 (A19654), bcl-2 associated X (bax, A19684), bcl-2 (A0208), E-cadherin (A11492), vimentin (A19607) all from ABclonal Technology (China); matrix metalloproteinase (MMP)-2 (10373-2-AP) and MMP-9 (10375-2-AP) both from Proteintech Group, Inc. (China); phosphorylated (p-) PI3K (Tyr358, AF3242), PI3K (AF6241), p-Akt (Ser473, AF0016), Akt (AF6261), and NOB1 (DF12216) all from Affinity Biosciences; β-actin (sc-4778) from Santa Cruz (USA); goat anti-rabbit IgG (A0208) and goat anti-mouse IgG (A0216) both from Beyotime.

Techniques: Over Expression, Transfection

MiR-107 overexpression repressed cell proliferation, migration, invasion, and the PI3K/Akt signaling pathway by regulation of NOB1 in FaDu cells. Cells were co-transfected with miR-107 mimics or mimics NC and the NOB1 overexpressing plasmid or the empty vector. (a) After co-transfection for 24 h or 48 h or 72 h, CCK-8 assay was used to measure cell proliferation. (b, c) Migratory and invasive abilities of cells at 48 h post-transfection were evaluated. Wound-healing assay: scale bar = 200 μm; Transwell assay: scale bar = 100 μm. (d, e) After co-transfection for 48 h, CDK4, bax, E-cadherin, p-PI3K, PI3K, p-Akt, and Akt protein expressions were assessed. Results were presented as means ± SD (n = 3). ^ P < 0.05 and ^^ P < 0.01 versus the miR-107 mimics+vector group.

Journal: Bioengineered

Article Title: Overexpression of microRNA-107 suppressed proliferation, migration, invasion, and the PI3K/Akt signaling pathway and induced apoptosis by targeting Nin one binding (NOB1) protein in a hypopharyngeal squamous cell carcinoma cell line (FaDu)

doi: 10.1080/21655979.2022.2051266

Figure Lengend Snippet: MiR-107 overexpression repressed cell proliferation, migration, invasion, and the PI3K/Akt signaling pathway by regulation of NOB1 in FaDu cells. Cells were co-transfected with miR-107 mimics or mimics NC and the NOB1 overexpressing plasmid or the empty vector. (a) After co-transfection for 24 h or 48 h or 72 h, CCK-8 assay was used to measure cell proliferation. (b, c) Migratory and invasive abilities of cells at 48 h post-transfection were evaluated. Wound-healing assay: scale bar = 200 μm; Transwell assay: scale bar = 100 μm. (d, e) After co-transfection for 48 h, CDK4, bax, E-cadherin, p-PI3K, PI3K, p-Akt, and Akt protein expressions were assessed. Results were presented as means ± SD (n = 3). ^ P < 0.05 and ^^ P < 0.01 versus the miR-107 mimics+vector group.

Article Snippet: The information of antibodies used in immunoblotting was as below: cyclin D1 (A19038), cyclin-dependent kinase 4 (CDK4, A0366), caspase-3 (A19654), bcl-2 associated X (bax, A19684), bcl-2 (A0208), E-cadherin (A11492), vimentin (A19607) all from ABclonal Technology (China); matrix metalloproteinase (MMP)-2 (10373-2-AP) and MMP-9 (10375-2-AP) both from Proteintech Group, Inc. (China); phosphorylated (p-) PI3K (Tyr358, AF3242), PI3K (AF6241), p-Akt (Ser473, AF0016), Akt (AF6261), and NOB1 (DF12216) all from Affinity Biosciences; β-actin (sc-4778) from Santa Cruz (USA); goat anti-rabbit IgG (A0208) and goat anti-mouse IgG (A0216) both from Beyotime.

Techniques: Over Expression, Migration, Transfection, Plasmid Preparation, Cotransfection, CCK-8 Assay, Wound Healing Assay, Transwell Assay

MiR-107 overexpression reduced the tumorigenic potential of FaDu HSCC in vivo . FaDu cells transfected with LV-based miR-107 or LV-NC were subcutaneously injected into the right armpit of the mice. (a) The tumor volume was measured every 3 days when the tumor was macroscopic. (b) At day 24, the tumor was collected and weighted. (c) The tumor tissues were stained with H&E. Scale bar = 100 μm. (d) The level of miR-107 was detected by RT-qPCR. (e) The expression of NOB1 was measured via IHC assay. Scale bar = 50 μm. (f) Evaluation of NOB1, p-PI3K, PI3K, p-Akt, and Akt protein expressions. Data were expressed as means ± SD (n = 6). &&& P < 0.001 versus the LV-NC group. LV, lentivirus.

Journal: Bioengineered

Article Title: Overexpression of microRNA-107 suppressed proliferation, migration, invasion, and the PI3K/Akt signaling pathway and induced apoptosis by targeting Nin one binding (NOB1) protein in a hypopharyngeal squamous cell carcinoma cell line (FaDu)

doi: 10.1080/21655979.2022.2051266

Figure Lengend Snippet: MiR-107 overexpression reduced the tumorigenic potential of FaDu HSCC in vivo . FaDu cells transfected with LV-based miR-107 or LV-NC were subcutaneously injected into the right armpit of the mice. (a) The tumor volume was measured every 3 days when the tumor was macroscopic. (b) At day 24, the tumor was collected and weighted. (c) The tumor tissues were stained with H&E. Scale bar = 100 μm. (d) The level of miR-107 was detected by RT-qPCR. (e) The expression of NOB1 was measured via IHC assay. Scale bar = 50 μm. (f) Evaluation of NOB1, p-PI3K, PI3K, p-Akt, and Akt protein expressions. Data were expressed as means ± SD (n = 6). &&& P < 0.001 versus the LV-NC group. LV, lentivirus.

Article Snippet: The information of antibodies used in immunoblotting was as below: cyclin D1 (A19038), cyclin-dependent kinase 4 (CDK4, A0366), caspase-3 (A19654), bcl-2 associated X (bax, A19684), bcl-2 (A0208), E-cadherin (A11492), vimentin (A19607) all from ABclonal Technology (China); matrix metalloproteinase (MMP)-2 (10373-2-AP) and MMP-9 (10375-2-AP) both from Proteintech Group, Inc. (China); phosphorylated (p-) PI3K (Tyr358, AF3242), PI3K (AF6241), p-Akt (Ser473, AF0016), Akt (AF6261), and NOB1 (DF12216) all from Affinity Biosciences; β-actin (sc-4778) from Santa Cruz (USA); goat anti-rabbit IgG (A0208) and goat anti-mouse IgG (A0216) both from Beyotime.

Techniques: Over Expression, In Vivo, Transfection, Injection, Staining, Quantitative RT-PCR, Expressing

Journal: Bioengineered

Article Title: Overexpression of microRNA-107 suppressed proliferation, migration, invasion, and the PI3K/Akt signaling pathway and induced apoptosis by targeting Nin one binding (NOB1) protein in a hypopharyngeal squamous cell carcinoma cell line (FaDu)

doi: 10.1080/21655979.2022.2051266

Figure Lengend Snippet:

Article Snippet: The information of antibodies used in immunoblotting was as below: cyclin D1 (A19038), cyclin-dependent kinase 4 (CDK4, A0366), caspase-3 (A19654), bcl-2 associated X (bax, A19684), bcl-2 (A0208), E-cadherin (A11492), vimentin (A19607) all from ABclonal Technology (China); matrix metalloproteinase (MMP)-2 (10373-2-AP) and MMP-9 (10375-2-AP) both from Proteintech Group, Inc. (China); phosphorylated (p-) PI3K (Tyr358, AF3242), PI3K (AF6241), p-Akt (Ser473, AF0016), Akt (AF6261), and NOB1 (DF12216) all from Affinity Biosciences; β-actin (sc-4778) from Santa Cruz (USA); goat anti-rabbit IgG (A0208) and goat anti-mouse IgG (A0216) both from Beyotime.

Techniques: CCK-8 Assay

Results of western blot analysis. (A) Representative western blots of rat chondrocytes. The average relative expression of (B) LC3II/I, (C) p-AKT/AKT and (D) p-mTOR/mTOR from rat chondrocytes. (E) Representative western blots of human chondrocytes. The average relative expression of (F) LC3II/I, (G) p-AKT/AKT, and (H) p-mTOR/mTOR from human chondrocytes. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Con, control group; DEX, dexamethasone group (200 µM); DEX + Li, dexamethasone (200 µM) combined with lithium chloride (10 mM) group; p-AKT, phosphorylated AKT; p-mTOR, phosphorylated mTOR; p-, phosphorylated.

Journal: Molecular Medicine Reports

Article Title: Lithium prevents glucocorticoid‑induced chondrocyte autophagy: An in vitro study

doi: 10.3892/mmr.2023.13070

Figure Lengend Snippet: Results of western blot analysis. (A) Representative western blots of rat chondrocytes. The average relative expression of (B) LC3II/I, (C) p-AKT/AKT and (D) p-mTOR/mTOR from rat chondrocytes. (E) Representative western blots of human chondrocytes. The average relative expression of (F) LC3II/I, (G) p-AKT/AKT, and (H) p-mTOR/mTOR from human chondrocytes. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001. Con, control group; DEX, dexamethasone group (200 µM); DEX + Li, dexamethasone (200 µM) combined with lithium chloride (10 mM) group; p-AKT, phosphorylated AKT; p-mTOR, phosphorylated mTOR; p-, phosphorylated.

Article Snippet: Subsequently, the membranes were incubated overnight at 4°C with primary antibodies against LC3B (rabbit; 1:2,000; cat. no. ab192890; Abcam), phosphorylated (p-)AKT (rabbit; 1:1,000; cat. no. 310021; Chengdu Zen Bioscience Co., Ltd.), AKT (rabbit; 1:1,000; cat. no. 382804; Chengdu Zen Bioscience Co., Ltd.), phosphorylated mTOR (mouse; 1:1,000; cat. no. sc-293133; Santa Cruz Biotechnology, Inc.), mTOR (mouse; 1:1,000; cat. no. sc-517464; Santa Cruz Biotechnology, Inc.), and β-tubulin (rabbit; 1:2,000; cat. no. AF7011; Affinity Biosciences).

Techniques: Western Blot, Expressing, Control

Treatment with angelicin alters the protein expression levels of PI3K, p-Akt and total Akt in HepG2 and Huh-7 cells in vitro . (A) Representative blots demonstrating PI3K, p-Akt and total Akt protein expression levels in HepG2 and Huh-7 cells, following treatment with various concentrations of angelicin. (B) PI3K blots were semi-quantified using densitometry analysis of the protein bands and normalized to GAPDH. (C) p-Akt/Akt blots were semi-quantified using densitometry analysis of the protein bands. (D) Effects of LY294002 on angelicin-induced apoptosis. Cells were treated with the PI3K inhibitor LY294002 (3 mM) for 1 h prior to treatment with angelicin. The percentage of apoptotic cells following treatment with angelicin in the presence or absence of LY294002 was assessed using Annexin V-fluorescein isothiocyanate/propidium iodide staining and flow cytometry. Data are expressed as the mean ± standard deviation of 3 independent experiments. *P<0.05, **P<0.01 vs. the control group (0 µM angelicin); # P<0.05 vs. the DMSO group. PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; p-, phosphorylated; DMSO, dimethyl sulfoxide; Akt, RAC-α serine/threonine-protein kinase.

Journal: Molecular Medicine Reports

Article Title: Angelicin inhibits liver cancer growth in vitro and in vivo

doi: 10.3892/mmr.2017.7219

Figure Lengend Snippet: Treatment with angelicin alters the protein expression levels of PI3K, p-Akt and total Akt in HepG2 and Huh-7 cells in vitro . (A) Representative blots demonstrating PI3K, p-Akt and total Akt protein expression levels in HepG2 and Huh-7 cells, following treatment with various concentrations of angelicin. (B) PI3K blots were semi-quantified using densitometry analysis of the protein bands and normalized to GAPDH. (C) p-Akt/Akt blots were semi-quantified using densitometry analysis of the protein bands. (D) Effects of LY294002 on angelicin-induced apoptosis. Cells were treated with the PI3K inhibitor LY294002 (3 mM) for 1 h prior to treatment with angelicin. The percentage of apoptotic cells following treatment with angelicin in the presence or absence of LY294002 was assessed using Annexin V-fluorescein isothiocyanate/propidium iodide staining and flow cytometry. Data are expressed as the mean ± standard deviation of 3 independent experiments. *P<0.05, **P<0.01 vs. the control group (0 µM angelicin); # P<0.05 vs. the DMSO group. PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase; p-, phosphorylated; DMSO, dimethyl sulfoxide; Akt, RAC-α serine/threonine-protein kinase.

Article Snippet: Polyclonal antibodies against PI3K (AF3242), Akt (AF6261), phosphorylated (p)-Akt (AF0016), apoptosis regulator BAX (Bax; AF0083) and Bcl-2 (AF6139) were purchased from Affinity Biologicals, Inc. (Ancaster, ON, Canada); antibodies against caspase-9 (9508T), caspase-3 (9665S), cytochrome c (4272S), Ki-67 (12075) and p-vascular endothelial growth factor receptor (VEGFR) 2 (9698) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

Techniques: Expressing, In Vitro, Staining, Flow Cytometry, Standard Deviation